Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518404

— · D

47dfe9b6-2e6b-55d7-8d76-6071e629aad4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • ANGIOGENESIS+0.410
  • NOTCH_SIGNALING+0.410
  • MYOGENESIS+0.400
  • MITOTIC_SPINDLE+0.370
  • TGF_BETA_SIGNALING+0.370
  • WNT_BETA_CATENIN_SIGNALING+0.350
  • APICAL_JUNCTION+0.340
  • HYPOXIA+0.340
  • TNFA_SIGNALING_VIA_NFKB+0.300

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.440
  • OXIDATIVE_PHOSPHORYLATION-0.410
  • PROTEIN_SECRETION-0.380
  • INTERFERON_GAMMA_RESPONSE-0.370
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
  • MYC_TARGETS_V1-0.320
  • ALLOGRAFT_REJECTION-0.310
  • ANDROGEN_RESPONSE-0.290
  • DNA_REPAIR-0.230
  • FATTY_ACID_METABOLISM-0.230

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518392
breast-umap@18
—D0.874
2SRR9879274
lung-landscapes@6
—cohortSQ10.854
3TCGA-A7-A0DA-01A-31R-A115-07
breast-umap@18
—E0.829
4TCGA-77-8145-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.821
5SRR27320666
colon-landscapes@1
——0.813
6SRR8613770
breast-umap@18
—E0.812
7f825534d-5882-4efe-a32e-af56741854f6
colon-landscapes@1
——0.809
8SRR8613760
breast-umap@18
—E0.808
9SRR8613779
breast-umap@18
—D0.787
10TCGA-F7-8298-01A-11R-2403-07
head-neck@1
——0.779

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
ANGIOGENESIS0.410Remibrutinib— uncovered
NOTCH_SIGNALING0.410Inavolisib— uncovered
MYOGENESIS0.400Inavolisib— uncovered
MITOTIC_SPINDLE0.370Inavolisib— uncovered
TGF_BETA_SIGNALING0.370Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.350Inavolisib— uncovered
APICAL_JUNCTION0.340Inavolisib— uncovered
HYPOXIA0.340Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.300Inavolisib— uncovered
UV_RESPONSE_DN0.270Inavolisib— uncovered
HEDGEHOG_SIGNALING0.230Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.200Remibrutinib— uncovered
KRAS_SIGNALING_DN0.200Remibrutinib— uncovered
APICAL_SURFACE0.160Temsirolimus— uncovered
E2F_TARGETS0.150Inavolisib— uncovered
G2M_CHECKPOINT0.120Inavolisib— uncovered
PANCREAS_BETA_CELLS0.120Cobimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.100Inavolisib— uncovered
MYC_TARGETS_V20.090Idelalisib— uncovered